|
|
|
|
Early oncology trial decisions can lock in risk, shape regulatory confidence, and limit flexibility. Knowing which choices are hardest to reverse protects optionality and credibility.
|
|
|
|
|
Pivotal Phase 3 trial tested whether brief neoadjuvant Leukocyte Interleukin Injection before surgery could improve outcomes in treatment‑naïve patients with resectable, locally advanced oral and soft‑palate SCCHN.
|
|
|
|
|
By integrating protocol design, site engagement, and oversight, Ergomed supported timely data reviews and adaptive trial changes, highlighting the strategic value a CRO delivers in complex oncology development.
|
|
|
|
|
This major Phase III rescue trial — one of the largest global head and neck cancer studies with 900+ patients — faced significant challenges, including enrollment delays, operational complexity, and a demanding study design.
|
|
|
|
|
Modern oncology needs adaptive, data-driven dose finding. Learn why traditional methods fall short and how model-assisted and model-based designs improve decisions.
|
|
|
|
|
|
|
|
|
